The testing and certification company SGS has announced the expansion of its analytical capabilities for the Chinese pharmaceutical industry with the introduction of nuclear magnetic resonance (NMR) testing.
The new service will offer qualitative and quantitative analysis for both drug substances and drug products, which SGS says will secure the highest standards of identity, purity and quality throughout drug development and manufacturing — helping its clients ensure that their drug products meet their promise.
NMR is a non-destructive analytical technique that reveals detailed molecular structures and compositions. It complements existing chromatographic and spectroscopic methods.
SGS said in its announcement that the method offers API structure confirmation and isomer differentiation, as well as impurity and degradation product identification down to 0.1% w/w.
The new NMR service offers cost-effective, high-throughput analysis, making it ideal for routine quality control, identity testing, purity assessment and quantitation of synthesised drug substances and raw materials.